Search

On May 5, 2021, the Colorado Department of Public Health and Environment (CDPHE) identified the first five COVID-19 cases caused by the SARS-CoV-2 B.1.617.2 (Delta) variant in Mesa County in western Colorado (population 154,933

A patient was seen on the palliative care service at our institution who developed serotonin syndrome and mutism associated with methadone use. Serotonin syndrome is often described as a clinical triad of mental status changes, autonomic hyperactivity, and neuromuscular abnormalities, but not all of these findings are consistently present in all patients with the disorder. The incidence of the serotonin syndrome is thought to mirror the increasing number of proserotonergic agents being used in clinical practice. In 2002, the Toxic Exposure Surveillance System, which receives case descriptions from office-based practices, inpatient settings, and emergency departments, reported 26,733 incidences of exposure to selective serotonin-reuptake inhibitors (SSRIs) that caused significant toxic effects in 7349 persons and resulted in 93 deaths. Serotonin syndrome is not an idiopathic drug reaction; it is a predictable consequence of excess serotonergic agonism of central nervous system (CNS) receptors and peripheral serotonergic receptors. The myriad of symptoms with which serotonin syndrome may present is compounded by the fact that more than 85% of physicians are unaware of serotonin syndrome as a clinical diagnosis. Other SSRIs such as fluoxetine and fluvoxamine have been shown to increase methadone plasma concentrations in dependent patients. Although the exact mechanism is unknown, there are several pathways via which a significant interaction could occur. This would include the effects methadone has on N-methyl-D-aspartate (NMDA) in addition to the impact of methadone on the cytochrome P450 enzyme system. The mainstay of treatment of serotonin syndrome is withdrawal of the offending agent and supportive care. These actions resulted in resolution of our patient's symptoms. Serotonin syndrome is becoming more common, and with the utilization of polypharmacy on many palliative care services should be considered as unifying differential diagnosis in the appropriate setting.

Menorrhagia is a common problem among women. The cause of which, in some individuals, has been attributed to von Willebrand’s disease. The assessment of this condition has been hampered by the lack of easily available and consistent laboratory assessment of levels of this factor that correlate with the patient’s clinical presentation. Therefore we initiated a study to correlate the patient’s self assessment of their menorrhagia with their levels of von Willebrand’s factor (VWF) and platelet function. A peripheral blood assessment chart (PBAC) was utilized for patient self-assessment of blood loss during their menstrual cycle. The PBAC is a validated, well-established method which utilized a point system that quantifies the number and extent of soiling of tampons and pads used during a patient’s menstrual cycle. The PFA-100 has been used as an adjunct for lab assessment of platelet function. This is a high shear-inducing device which simulates primary hemostasis after injury to small vessel. This apparatus consists of a reservoir for whole blood and a small capillary surmounted by a collagen-coated membrane with a central aperture. Platelet agonist which is either epinephrine or ADP is present on the membrane. Closure time is reported as a variable which inversely corresponds with von Willebrand factor levels (or platelet function). Clinical correlation with its results are needed. In addition, blood samples were analyzed for Von Willebrand’s factor antigen (VWFA) and Ristocetin co-factor activity (RCOA) using a CLIA approved laboratory. We explored the relationship between PBAC, PFA-100 and VWFA and RCOA levels. Twenty-six patients were enrolled after obtaining an institutional board approved informed consent. Pearson association estimates and P values to assess the association between one month PBAC scores and PFA-100 showed 0.463 (with a p-value of 0.017). A similar analysis between one month PBAC scores and VWFA and RCOA showed 0.099 (p=0.632) and the association between PFA-100 and VWFA and RCOA showed an inverse relationship of −0.481 (p=0.013). These results confirm a correlation between VWFA and RCOA and assessment of platelet function utilizing a PFA-100. Furthermore, there was a correlation between PBAC scores and the results of the PFA-100. The association between PBAC scores and VWAF screening levels did not show significance. These results suggest further data are necessary to understand the relationship between these variables and further suggests that the PFA-100 may offer a more sensitive assessment of platelet function that correlates with clinical presentation than levels of VWFA or RCOA.